Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Valbiotis SA ( (FR:ALVAL) ) has shared an update.
Valbiotis has announced its monthly information on the total number of voting rights and shares making up its share capital as of February 28, 2025. The company emphasizes the importance of compliance with its statutes regarding threshold crossings, which require shareholders to notify the company if their holdings reach certain percentages of the company’s capital. This announcement highlights Valbiotis’ commitment to transparency and regulatory compliance, which is crucial for maintaining investor confidence and ensuring proper governance.
More about Valbiotis SA
Valbiotis is a French scientific research laboratory that specializes in the commercialization of scientifically validated dietary supplements aimed at preventing metabolic and cardiovascular diseases. The company focuses on developing innovative health nutrition products using terrestrial and marine plants, and has established partnerships with top academic centers. Valbiotis is recognized as an ‘Innovative Company’ and has received financial support from the European Union.
YTD Price Performance: -23.50%
Average Trading Volume: 1,709
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €16.89M
For detailed information about ALVAL stock, go to TipRanks’ Stock Analysis page.